DISCOVER

Our News

1 july 2025 - Carthera is one of the first companies to benefit from brand-new status - intended to support early access pathways for innovative devices targeting rare diseases.

22 april 2025 - First 100 participants enrolled across Europe and US in largest trial ever performed on glioblastoma patients using ultrasound-based blood-brain barrier opening.

28 january 2025 - Dr Adam Sonobend, from Northwerstern Medicine, discuss the use of the SonoCloud-9 technology for drug delivery for malignant gliomas.

1 july 2024 - Following positive opinion, ultrasound-based medical device company will obtain temporary funding to conduct first registrational trial of SonoCloud® device in France.

14 may 2024 - Orphan designation shows recognition of enhanced therapeutic potential of carboplatin when used with Carthera’s SonoCloud® technology.

9 april 2024 - World-first trial could change standard of care for unmethylated glioblastoma patients.

5 march 2024 - Results demonstrate safety and potential efficacy of SonoCloud-9® in treating recurrent glioblastoma.

February 5, 2024 - Registrational study aims to enroll 560 US and EU patients over next two years, with view to obtaining marketing authorization.

December 11, 2023 - Carthera announces an additional €4.5M in funding to complement its Series B financing round, bringing the total raised to €42M ($45M).

November 6, 2023 - Carthera announces the signing of a strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company, for the supply of carboplatin.